CA3033964A1 - Gaba(a) receptor modulators and methods to control airway hyperresponsiveness and inflammation in asthma - Google Patents

Gaba(a) receptor modulators and methods to control airway hyperresponsiveness and inflammation in asthma Download PDF

Info

Publication number
CA3033964A1
CA3033964A1 CA3033964A CA3033964A CA3033964A1 CA 3033964 A1 CA3033964 A1 CA 3033964A1 CA 3033964 A CA3033964 A CA 3033964A CA 3033964 A CA3033964 A CA 3033964A CA 3033964 A1 CA3033964 A1 CA 3033964A1
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
cyclopropyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3033964A
Other languages
English (en)
French (fr)
Inventor
Alexander E. Arnold
Douglas C. Stafford
James M. Cook
Charles W. Emala
Gloria FORKUO
Rajwana JAHAN
Revathi KODALI
Guanguan LI
Michael Rajesh Stephen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University
UWM Research Foundation Inc
Original Assignee
Columbia University
UWM Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University, UWM Research Foundation Inc filed Critical Columbia University
Publication of CA3033964A1 publication Critical patent/CA3033964A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3033964A 2016-08-16 2017-08-16 Gaba(a) receptor modulators and methods to control airway hyperresponsiveness and inflammation in asthma Pending CA3033964A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662375694P 2016-08-16 2016-08-16
US62/375,694 2016-08-16
US201662427771P 2016-11-29 2016-11-29
US62/427,771 2016-11-29
PCT/US2017/047185 WO2018035246A1 (en) 2016-08-16 2017-08-16 Gaba(a) receptor modulators and methods to control airway hyperresponsiveness and inflammation in asthma

Publications (1)

Publication Number Publication Date
CA3033964A1 true CA3033964A1 (en) 2018-02-22

Family

ID=59714151

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3033964A Pending CA3033964A1 (en) 2016-08-16 2017-08-16 Gaba(a) receptor modulators and methods to control airway hyperresponsiveness and inflammation in asthma

Country Status (8)

Country Link
US (2) US11447495B2 (enExample)
EP (1) EP3500573B1 (enExample)
JP (1) JP7013446B2 (enExample)
CN (1) CN109790170B (enExample)
AU (1) AU2017313753B2 (enExample)
CA (1) CA3033964A1 (enExample)
ES (1) ES2895965T3 (enExample)
WO (1) WO2018035246A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI878507B (zh) 2020-03-31 2025-04-01 瑞士商赫孚孟拉羅股份公司 作為 GABA A γ1 PAM 的新穎苯并二氮呯衍生物
EP3901155A1 (en) * 2020-04-20 2021-10-27 F. Hoffmann-La Roche AG New benzodiazepine derivatives as gaba a gamma1 pam
JP2024537773A (ja) 2021-09-29 2024-10-16 エフ． ホフマン－ラ ロシュ アーゲー ＧＡＢＡ Ａγ１ ＰＡＭとしての新規ベンゾジアゼピン誘導体
WO2023057415A1 (en) 2021-10-06 2023-04-13 F. Hoffmann-La Roche Ag Benzodiazepine derivatives as positive allosteric modulators of the gaba a gamma1 receptor
WO2023059443A1 (en) * 2021-10-07 2023-04-13 Pantherics Incorporated Methods and compounds for treating inflammation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA755418B (en) 1974-09-11 1977-06-29 Hoffmann La Roche Diazepine derivatives
US4125726A (en) 1977-03-11 1978-11-14 Hoffmann-La Roche Inc. Imidazo[1,5-a][1,4]benzodiazepines
US4401597A (en) 1978-05-15 1983-08-30 Hoffmann-La Roche Inc. Imidazodiazepines and processes therefor
US4226768A (en) * 1979-05-29 1980-10-07 Hoffmann-La Roche Inc. Process for the preparation of imidazobenzodiazepines
US4238610A (en) 1979-12-20 1980-12-09 Hoffmann-La Roche Inc. Intermediates for the production of imidazobenzodiazepines
ZA845757B (en) 1983-08-25 1985-04-24 Hoffmann La Roche Benzodiazepine derivatives
US5317018A (en) 1992-06-09 1994-05-31 Armin Walser Benzodiazepines and compositions for treating anxiety and panic disorders, and idiopathic and psychomotor epilepsy
TW349100B (en) * 1994-11-11 1999-01-01 Hoffmann La Roche Oxazolyl- and thiazolylimidazo-benzo- and thienodiazepines
CA2184802C (en) 1995-10-10 2007-07-31 Karl-Heinz Bender Process for manufacture of imidazo benzodiazepine derivatives
GB9911152D0 (en) 1999-05-14 1999-07-14 Glaxo Group Ltd Short-acting benzodiazepines
US20010014738A1 (en) 1999-06-30 2001-08-16 Madhup K. Dhaon Process for the preparation of imidazodiazepine intermediates
US6512114B1 (en) 1999-06-30 2003-01-28 Abbott Laboratories Process for the preparation of Midazolam
US6262260B1 (en) 2000-03-23 2001-07-17 Abbott Laboratories Process for the preparation of midazolam
WO2003082832A2 (en) 2002-03-28 2003-10-09 Wisys Technology Foundation, Inc. Anxiolytic agents with reduced sedative and ataxic effects
US8835424B2 (en) 2002-03-28 2014-09-16 Wisconsin Alumni Research Foundation Selective agents for pain suppression
MXJL06000069A (es) * 2004-06-09 2007-04-10 Avanir Pharmaceuticals Derivados heterociclicos para el tratamiento de hiperlipidemia y enfermedades relacionadas.
AU2005260650A1 (en) * 2004-06-30 2006-01-12 Wisys Technology Foundation, Inc. Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects
US7595395B2 (en) * 2005-05-16 2009-09-29 Wisys Technology Foundation Gabaergic agents to treat memory deficits
US8119629B2 (en) 2007-10-03 2012-02-21 Bristol-Meyers Squibb Company Carboxamide GABAA α2 modulators
US20100261711A1 (en) 2009-03-20 2010-10-14 Wisys Technology Foundation Selective anticonvulsant agents and their uses
IT1399764B1 (it) 2010-05-04 2013-05-03 F S I Fabbrica Italiana Sint Procedimento per la sintesi di 4h-imidazo [1,5-a][1,4]benzodiazepine, in particolare di midazolam.
US9006233B2 (en) * 2011-04-28 2015-04-14 Uwm Research Foundation, Inc. Gabaergic receptor subtype selective ligands and their uses
WO2012162254A1 (en) * 2011-05-23 2012-11-29 Elan Pharmaceuticals, Inc. Inhibitors of lrrk2 kinase activity
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
CN103204838B (zh) 2012-01-13 2017-06-09 北京盛诺基医药科技有限公司 多羟基苯并吡喃酮类化合物的合成及其抗肿瘤作用
CN103319486B (zh) 2012-03-22 2017-10-10 徐州市心血管病研究所 合成4H‑咪唑并[1,5‑a][1,4]苯二氮卓,特别是咪达唑仑的方法
CA2885148A1 (en) * 2012-09-21 2014-03-27 Uwm Research Foundation, Inc. Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma
EP4129297A1 (en) 2016-03-18 2023-02-08 UWM Research Foundation, Inc. Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists

Also Published As

Publication number Publication date
BR112019003065A2 (pt) 2019-05-21
WO2018035246A1 (en) 2018-02-22
AU2017313753A1 (en) 2019-03-07
JP7013446B2 (ja) 2022-02-15
EP3500573A1 (en) 2019-06-26
JP2019528267A (ja) 2019-10-10
AU2017313753B2 (en) 2022-01-27
CN109790170B (zh) 2022-08-02
US12054491B2 (en) 2024-08-06
US11447495B2 (en) 2022-09-20
US20230103216A1 (en) 2023-03-30
EP3500573B1 (en) 2021-10-06
US20210284649A1 (en) 2021-09-16
ES2895965T3 (es) 2022-02-23
CN109790170A (zh) 2019-05-21

Similar Documents

Publication Publication Date Title
US12054491B2 (en) Substituted benzo[f]imidazo[1,5-a][1,4]diazepines as GABA(a) receptor modulators
CN110088105B (zh) Jak家族激酶的小分子抑制剂
JP5874878B2 (ja) 複素二環スピロ化合物又はその薬学的に許容される塩、これらの化合物を含む医薬組成物、および哺乳類のアルツハイマー病及びインスリン抵抗性症候群及び２型糖尿病を治療するための薬剤の調整における、これらの化合物の利用
TW200913990A (en) Novel compounds 951
WO2017201069A1 (en) Oxoindoline derivatives as protein function modulators
JP5809279B2 (ja) リバースターン類似体の新規な化合物およびその製造方法と用途
WO2012054332A1 (en) Substituted hydroxamic acids and uses thereof
PT1354884E (pt) Composto de ciclopenta (d) pirazolo [1,5-a] piramida como antagonista de receptor de crf
JP7125495B2 (ja) テトラヒドロイソキノリン化合物、その調製方法、そのような化合物を含む医薬組成物およびその使用
WO2018108969A1 (en) Aminopyrazoles as selective janus kinase inhibitors
US20190300534A1 (en) Gabaergic ligands and their uses
CN110573497A (zh) 组蛋白脱乙酰基酶抑制剂
CN112313233A (zh) Jak家族激酶的小分子抑制剂
HUP0400819A2 (hu) 4-(Bifenil-karbonil-amino)-piperidin-származékok, mint MTP inhibitorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
US9879020B2 (en) GABAA agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma
CN103189367A (zh) 色烯衍生物
TW202320755A (zh) 三環化合物及其製備方法
JP2025515098A (ja) シトクロムｂｄオキシダーゼ阻害剤およびその使用
BR112019003065B1 (pt) Compostos moduladores do receptor gaba(a) ou sais farmaceuticamente aceitável dos mesmos, composição farmacêutica e forma de dosagem unitária compreendendo ditos compostos e usos terapêuticos dos mesmos
WO2026082108A1 (zh) 一种nlrp3抑制剂用于治疗帕金森病或帕金森综合征的用途
HK40038640B (en) Fused tri-cyclic compound as pde3/pde4 dual inhibitor
HK40038640A (en) Fused tri-cyclic compound as pde3/pde4 dual inhibitor

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220809

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240809

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240809

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240809

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241009

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250131

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250526

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250526

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250808

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250808